Prospective Disease-Specific Priority Setting

Establishing Disease-Specific Strategic Frameworks to Guide Concept Development and Evaluation

Jeff Abrams, MD
Associate Director, CTEP, DCTD
Disease-Specific Priority Setting Principles

• Set strategic priorities for NCTN trials in advance

• Majority of concepts expected to align with strategic priorities

• Trial concepts outside strategic priorities still considered, but may require additional justification

• NCTN Groups responsible for concept development

• Steering Committees continue to evaluate all concepts rigorously for scientific and clinical quality regardless of alignment with strategic priorities
Process for Setting Disease-Specific Strategic Priorities

• Assess strategic clinical trials landscape within the disease to identify gaps and provide context

• Discuss strategic priorities under the aegis of the Steering Committees
  – NCTN Groups propose strategic priorities for discussion, ideally with cross-Group collaboration
  – Outside input solicited as needed

• Goal to select a few major priorities for each disease

• Priorities reviewed annually and revised as needed
NCI Support for Setting Disease-Specific Strategic Priorities

- Collaborative process with full involvement of relevant NCTN Groups and SCs
- Process flexible and implemented somewhat differently for different diseases
- NCI to provide additional administrative support
- Process may be conducted using standard SC monthly conference calls, additional ad hoc calls, and/or in-person meetings

- Final Prospective *Strategic Priority Setting* document due to NCI June 15, 2015
- Priorities reviewed by NCTN Groups and SCs annually and revised as needed through a collaborative process
Periodic Strategic Assessment of Scientific Steering Committee Portfolios
Periodic assessment of trial portfolios would be valuable
- Provides essential feedback to the Steering Committees & Groups/Research Bases
- Ensures that trials address the strategic priorities established for the portfolios

General support for “self-assessment” by the Steering Committees augmented with additional NCTN Group/NCORP Research Base portfolio experts

Portfolio-specific assessments by SCs should be subject to a higher level review across portfolios by an oversight group (e.g., CTAC Subcommittee or Working Group including the NCTN Group Chairs)

The next strategic assessment of all portfolios should begin 3-5 years from the initial NCTN WG review
Overarching Principles for Periodic Strategic Assessment

- Next portfolio-specific assessments performed by Steering Committees augmented with additional Group/Research Base portfolio experts as needed
  - Begins in 2016
  - Assessment process sets the stage for a comprehensive examination of strategic priorities across portfolios

- Oversight assessment group under auspices of CTAC performs two functions
  - Analyzes quality of the SC portfolio-specific assessments
  - Performs cross-portfolio analysis

- Cross-portfolio analysis could include the following
  - Overall cross-portfolio quality
  - Cross-portfolio recommendations
  - Value of the assessment process
  - Recommendations for future assessments

- Potential members of CTAC assessment group: CTAC Strategic Planning Subcommittee members plus Group Chairs/Statisticians